IGI Logo

Zydus Lifesciences is currently trading at Rs. 940.00, up by 17.80 points or 1.93% from its previous closing of Rs. 922.20 on the BSE.

The scrip opened at Rs. 935.15 and has touched a high and low of Rs. 950.30 and Rs. 935.15 respectively. So far 969 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1031.30 on 01-Apr-2024 and a 52 week low of Rs. 482.55 on 22-May-2023.

Last one week high and low of the scrip stood at Rs. 971.70 and Rs. 913.25 respectively. The current market cap of the company is Rs. 92794.90 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.35% and 6.66% respectively.

Zydus Lifesciences has launched Mirabegron Extended-Release Tablets, 25 mg in the US market. The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg (USRLD: Myrbetriq Extended-Release Tablets). Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market and is prepared to launch Mirabegron Extended-Release Tablets, 50mg imminently.

Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India.

Mirabegron Extended-Release Tablets USP 25mg and 50mg had annual sales of $2.42 billion in the US (IQVIA MAT February 2024). The group now has 393 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.